Synergistic Activity between Statins and Bisphosphonates against Acute Experimental Toxoplasmosis
Open Access
- 1 August 2017
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 61 (8)
Abstract
Bisphosphonates are widely used for the treatment of bone disorders. These drugs also inhibit the growth of a variety of protozoan parasites, such as Toxoplasma gondii , the etiologic agent of toxoplasmosis. The target of the most potent bisphosphonates is the isoprenoid biosynthesis pathway enzyme farnesyl diphosphate synthase (FPPS). Based on our previous work on the inhibitory effect of sulfur-containing linear bisphosphonates against T. gondii , we investigated the potential synergistic interaction between one of these derivatives, 1-[( n -heptylthio)ethyl]-1,1-bisphosphonate (C7S), and statins, which are potent inhibitors of the host 3-hydroxy-3-methyl glutaryl-coenzyme A reductase (3-HMG-CoA reductase). C7S showed high activity against the T. gondii bifunctional farnesyl diphosphate (FPP)/geranylgeranyl diphosphate (GGPP) synthase (TgFPPS), which catalyzes the formation of FPP and GGPP (50% inhibitory concentration [IC 50 ] = 31 ± 0.01 nM [mean ± standard deviation]), and modest effect against the human FPPS (IC 50 = 1.3 ± 0.5 μM). We tested combinations of C7S with statins against the in vitro replication of T. gondii . We also treated mice infected with a lethal dose of T. gondii with similar combinations. We found strong synergistic activities when using low doses of C7S, which were stronger in vivo than when tested in vitro . We also investigated the synergism of several commercially available bisphosphonates with statins both in vitro and in vivo . Our results provide evidence that it is possible to develop drug combinations that act synergistically by inhibiting host and parasite enzymes in vitro and in vivo .Keywords
Funding Information
- HHS | National Institutes of Health (AI-102254)
- MINCyT | Agencia Nacional de Promoción Científica y Tecnológica (PICT 2012 #0457)
- Consejo Nacional de Investigaciones Científicas y Técnicas (PIP 0797)
- Universidad de Buenos Aires (20020130100223BA)
This publication has 36 references indexed in Scilit:
- Toxoplasma gondii Relies on Both Host and Parasite Isoprenoids and Can Be Rendered Sensitive to AtorvastatinPLOS Pathogens, 2013
- Design, synthesis and biological evaluation of sulfur-containing 1,1-bisphosphonic acids as antiparasitic agentsEuropean Journal of Medicinal Chemistry, 2013
- Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosisProceedings of the National Academy of Sciences, 2012
- New antibacterials for the treatment of toxoplasmosis; a patent reviewExpert Opinion on Therapeutic Patents, 2012
- Bisphosphonates: The first 40yearsBone, 2011
- Apicoplast isoprenoid precursor synthesis and the molecular basis of fosmidomycin resistance in Toxoplasma gondiiJournal of Experimental Medicine, 2011
- Targeting Isoprenoid Biosynthesis for Drug Discovery: Bench to BedsideAccounts of Chemical Research, 2010
- Lipophilic Bisphosphonates as Dual Farnesyl/Geranylgeranyl Diphosphate Synthase Inhibitors: An X-ray and NMR InvestigationJournal of the American Chemical Society, 2009
- Toxoplasma gondii Tic20 is essential for apicoplast protein importProceedings of the National Academy of Sciences, 2008
- Nitrogen-Containing Bisphosphonates as Carbocation Transition State Analogs for Isoprenoid BiosynthesisBiochemical and Biophysical Research Communications, 1999